Overview

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Brimonidine Tartrate
Latanoprost
Lubricant Eye Drops
Ophthalmic Solutions
Pharmaceutical Solutions
Tetrahydrozoline
Criteria
Inclusion Criteria:

- Ocular hypertension or glaucoma in at least 1 eye

- Visual acuity of 20/100 or better in both eyes

Exclusion Criteria:

- Corneal refractive laser surgery (LASIK, LASEK, PRK, RK) in the study eye(s)

- Intraocular or glaucoma surgery in the past 3 months